We presently analyzed 8 gene polymorphisms involving 5 relevant candidate genes potentially related to the pharmacodynamics of cetuximab, namely EGFR, EGF, CCND1, FCGR2A and FCGR3A, on 58 CRC patients receiving cetuximab-based therapy. Here, FCGR3A is linked to colorectal carcinoma.